gutflix
GI learning, personalised

Summary

META-ANALYSIS: REAL-WORLD EFFECTIVENESS AND SAFETY OF DARVADSTROCEL FOR COMPLEX PERIANAL FISTULIZING CROHN'S DISEASE

Cristina Alba López

UEG Week Vienna 2024 | Poster

IBD

October 13, 2024

A systematic review and meta-analysis of 12 real-world observational studies (595 patients) evaluated darvadstrocel, an allogenic mesenchymal stem cell therapy, for complex perianal fistulas in Crohn's disease.

KEY POINTS

- Clinical remission (closure of all treated external openings) was achieved in 68.1% of patients at month 6 and 77.2% at month 12, with median time to fistula closure of 6 weeks.
- Combined remission (clinical remission plus absence of collections greater than 2 cm on MRI) was reported in 60.6% of patients at month 6 and 69.7% at month 12.
- Treatment failure rate at last follow-up (mean 18.7 months) was 34.5%, and linear regression indicated failure rate was independent of follow-up time.
- Incidence rates per 100 patient-years were 19.6 for adverse events, 3.2 for serious adverse events, 16.9 for new perianal abscesses, and 7.1 for reoperations.
- Heterogeneity across studies was not important for effectiveness outcomes but ranged from moderate to substantial for safety outcomes.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/2b361f78-9111-11ef-a6dd-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.